KoBioLabs Statistics

Total Valuation

KoBioLabs has a market cap or net worth of KRW 83.31 billion. The enterprise value is 61.67 billion.

Market Cap	83.31B
Enterprise Value	61.67B

Important Dates

The last earnings date was Friday, March 21, 2025.

Earnings Date	Mar 21, 2025
Ex-Dividend Date	n/a

Share Statistics

KoBioLabs has 19.37 million shares outstanding. The number of shares has increased by 3.65% in one year.

Current Share Class	n/a
Shares Outstanding	19.37M
Shares Change (YoY)	+3.65%
Shares Change (QoQ)	+0.32%
Owned by Insiders (%)	29.91%
Owned by Institutions (%)	0.29%
Float	13.53M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.21
PB Ratio	2.21
P/TBV Ratio	2.24
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-11.64
EV / Sales	0.90
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-10.29

Financial Position

The company has a current ratio of 4.82, with a Debt / Equity ratio of 0.30.

Current Ratio	4.82
Quick Ratio	4.28
Debt / Equity	0.30
Debt / EBITDA	n/a
Debt / FCF	-2.76
Interest Coverage	-5.96

Financial Efficiency

Return on equity (ROE) is -7.87% and return on invested capital (ROIC) is -5.67%.

Return on Equity (ROE)	-7.87%
Return on Assets (ROA)	-3.98%
Return on Invested Capital (ROIC)	-5.67%
Return on Capital Employed (ROCE)	-7.82%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.63
Inventory Turnover	7.27

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.50% in the last 52 weeks. The beta is 0.68, so KoBioLabs's price volatility has been lower than the market average.

Beta (5Y)	0.68
52-Week Price Change	-45.50%
50-Day Moving Average	4,850.30
200-Day Moving Average	6,175.80
Relative Strength Index (RSI)	20.22
Average Volume (20 Days)	27,622

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KoBioLabs had revenue of KRW 68.36 billion and -5.30 billion in losses. Loss per share was -276.00.

Revenue	68.36B
Gross Profit	46.79B
Operating Income	-6.91B
Pretax Income	-4.18B
Net Income	-5.30B
EBITDA	-4.33B
EBIT	-6.91B
Loss Per Share	-276.00

Full Income Statement

Balance Sheet

The company has 55.83 billion in cash and 16.54 billion in debt, giving a net cash position of 39.29 billion or 2,027.99 per share.

Cash & Cash Equivalents	55.83B
Total Debt	16.54B
Net Cash	39.29B
Net Cash Per Share	2,027.99
Equity (Book Value)	55.48B
Book Value Per Share	1,947.11
Working Capital	52.86B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.36 billion and capital expenditures -1.64 billion, giving a free cash flow of -6.00 billion.

Operating Cash Flow	-4.36B
Capital Expenditures	-1.64B
Free Cash Flow	-6.00B
FCF Per Share	-309.46

Full Cash Flow Statement

Margins

Gross margin is 68.45%, with operating and profit margins of -10.10% and -7.75%.

Gross Margin	68.45%
Operating Margin	-10.10%
Pretax Margin	-6.11%
Profit Margin	-7.75%
EBITDA Margin	-6.33%
EBIT Margin	-10.10%
FCF Margin	n/a

Dividends & Yields

KoBioLabs does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.65%
Shareholder Yield	-3.65%
Earnings Yield	-6.36%
FCF Yield	-7.20%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KoBioLabs has an Altman Z-Score of 0.64. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.64
Piotroski F-Score	n/a